Theranos promised laboratory results from a finger-stick. After 2015 reporting and a 2022 federal verdict, Elizabeth Holmes was convicted of fraud against investors.
Also called: Elizabeth Holmes · Edison blood-test claim
Theranos, Inc., a Palo Alto company founded by Elizabeth Holmes, told investors, partners, and the public that its devices — marketed under names including Edison — could run a wide menu of laboratory tests from a few drops of blood. At its peak the private company was valued in the press at about $9 billion (2014).
On 15 October 2015 the Wall Street Journal published John Carreyrou’s investigation reporting that the firm used conventional machines for many tests and that the proprietary devices were not doing what the company claimed. Federal and state health regulators, the SEC, and the Department of Justice followed with inspections, civil charges, and criminal indictments.
A jury in the U.S. District Court for the Northern District of California convicted Holmes on 3 January 2022 of conspiracy to commit wire fraud and three counts of wire fraud against investors. Judge Edward J. Davila sentenced her on 18 November 2022 to 135 months in prison. Ramesh ‘Sunny’ Balwani, the former president and chief operating officer, was convicted in July 2022 and later sentenced to 155 months. Patient-related counts against Holmes did not produce convictions.
Break yearWSJ, 2015
PlacePalo Alto, United States
CourtU.S. District, NDCA
Holmes verdictGuilty (Jan 2022)
Holmes sentence11+ years (2022)
StatusConvicted
Dossier scores
Notoriety 88
Mystery 25
Scale 70
Evidence 80
Legal impact 68
Culture 86
Notoriety
88
Mystery
25
Scale
70
Evidence
80
Legal impact
68
Culture
86
What the Theranos record actually shows
The Journal’s 2015 series, CMS inspection files, the SEC complaint, and two federal criminal trials in San Jose are the primary sources. They describe investor fraud proved to a jury, not a scientific mystery still waiting for a device.
A device claim and a retail partnership
Theranos raised capital on the promise of decentralized, low-volume blood testing. A 2013 partnership with Walgreens put collection sites in stores and made the claim a consumer-facing fact, not only a Silicon Valley pitch.
Internal and later public records showed that many tests offered to patients were run on third-party analyzers, sometimes after diluting small samples, while the company’s own devices handled a narrower set. That gap is the factual core of the later fraud cases.
Journalism, then regulators
Carreyrou’s October 2015 article, followed by more Journal reporting, forced the company into a defensive public posture. CMS inspected the Newark, California laboratory and in 2016 imposed sanctions, including a ban on Holmes’s operating labs for a period.
The FDA and CMS files, plus later SEC charges in March 2018, moved the story from a magazine dispute into the enforcement docket. The company dissolved in 2018 as the criminal case was prepared.
Two trials in San Jose
Holmes’s trial (2021–2022) focused on what investors were told about technology, pharmaceutical-company validation, and the Department of Defense. The jury convicted on investor-fraud counts and acquitted or hung on others, including patient-related wire-fraud counts.
Balwani was tried separately in 2022 and convicted on all counts he faced, including investor and patient-related fraud. The split outcomes are part of the public record and are often flattened in casual retellings.
What the case is not
Theranos is not an unsolved scientific puzzle. Courts treated the investor representations as false. Remaining argument is about sentence length, appeal points, and how much patient harm the Holmes verdict legally found.
The case is also not a general indictment of all finger-stick or point-of-care testing. Other devices are regulated and cleared on their own files. The encyclopedia entry is about this company’s claims and these dockets.
The company claimed its devices could run a broad menu of clinical laboratory tests from a finger-stick or other small sample, faster and cheaper than a conventional venous draw sent to a central lab.
When did the public case break?
The Wall Street Journal published John Carreyrou’s first major investigation on 15 October 2015. CMS sanctions, SEC charges (2018), and criminal trials followed.
What was Elizabeth Holmes convicted of?
On 3 January 2022 a Northern District of California jury convicted her of conspiracy to commit wire fraud and three counts of wire fraud involving investors. She was acquitted on several other counts, including patient-related wire-fraud counts.
What sentence did she receive?
Judge Edward J. Davila sentenced Holmes on 18 November 2022 to 135 months (11 years and 3 months) in federal prison, plus supervised release and restitution to be determined in the judgment papers.
What happened to Sunny Balwani?
Ramesh Balwani was convicted in July 2022 on all twelve counts he faced, including investor and patient-related fraud, and was sentenced in December 2022 to 155 months.
Did patients receive inaccurate results?
CMS findings and trial evidence included inaccurate or unreliable results from the Newark lab. Holmes was not convicted on the patient-fraud counts; Balwani was. Civil and regulatory files address laboratory quality separately from those verdicts.
What was the peak valuation?
Press accounts in 2014 put Theranos at about $9 billion as a private company. That figure was a fundraising mark, not a public-market capitalization, and it vanished with the 2018 wind-down.
Are the convictions on appeal?
Both Holmes and Balwani pursued Ninth Circuit appeals after sentencing. The encyclopedia treats the 2022 verdicts and sentences as the trial-court record; later appellate dispositions should be read from the docket.